Sule Comert1, Gul Karakaya1, Ali Fuat Kalyoncu1. 1. Department of Chest Diseases, Division of Allergy and Clinical Immunology, School of Medicine, Hacettepe University, Ankara, Turkey.
Abstract
BACKGROUND: Allergen avoidance is important for allergic rhinitis management. However, studies evaluating the efficiency of avoidance measures from pollens are lacking. We aimed to investigate the efficiency of wraparound eyeglasses in seasonal allergic rhinoconjunctivitis (SAR). METHODS:Eligible patients with a diagnosis of SAR (n = 70) rated theirsymptom scores, filled the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and were randomized either to receive wraparound eyeglasses in addition to medical treatment (group 1, n = 39) or medical treatment only (group 2, n = 31) throughout the 3 pollen seasons in the years 2011, 2012, and 2013. Patients rated their symptom scores and checked the need for use of rescue medications in their diaries over a period of 4 weeks. RQLQ was reapplied 1 week and 4 weeks after randomization. RESULTS: The median (interquartile range [IQR]) change from baseline over 4 weeks in the eye itching (-2.51 [-3.65 to -1.36] vs -0.88 [-1.95 to 0.43], p < 0.001), eye watering (-2.31 [-3.09 to -1.24] vs -1.60 [-2.59 to -0.21], p = 0.02), sneezing (-2.26 [-3.19 to -1.51] vs -1.68 [-2.27 to -0.56], p = 0.03), and rhinorrhea (-2.48 [-3.74 to -1.49] vs -1.59 [-2.88 to -0.87], p = 0.04) scores were significantly higher in group 1 compared to group 2. There were significantly higher improvements in ocular symptoms domain score (-1.75 [-3.12 to -1.00] vs -0.50 [-2.31 to -0.31], p = 0.002), nasal symptoms domain score (-2.25 [-4.06 to -1.50] vs -1.25 [-2.37 to -0.68], p = 0.004), and total RQLQ score (-1.98 [-2.67 to -0.88] vs -1.10 [-2.06 to -0.25], p = 0.02) and reduced need for rescue medication use in group 1 compared to group 2 at the end of 4 weeks. CONCLUSION: Standard wraparound eyeglasses can provide a safe, convenient, and effective measure for protection from pollens in patients with SAR.
RCT Entities:
BACKGROUND: Allergen avoidance is important for allergic rhinitis management. However, studies evaluating the efficiency of avoidance measures from pollens are lacking. We aimed to investigate the efficiency of wraparound eyeglasses in seasonal allergic rhinoconjunctivitis (SAR). METHODS: Eligible patients with a diagnosis of SAR (n = 70) rated their symptom scores, filled the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and were randomized either to receive wraparound eyeglasses in addition to medical treatment (group 1, n = 39) or medical treatment only (group 2, n = 31) throughout the 3 pollen seasons in the years 2011, 2012, and 2013. Patients rated their symptom scores and checked the need for use of rescue medications in their diaries over a period of 4 weeks. RQLQ was reapplied 1 week and 4 weeks after randomization. RESULTS: The median (interquartile range [IQR]) change from baseline over 4 weeks in the eye itching (-2.51 [-3.65 to -1.36] vs -0.88 [-1.95 to 0.43], p < 0.001), eye watering (-2.31 [-3.09 to -1.24] vs -1.60 [-2.59 to -0.21], p = 0.02), sneezing (-2.26 [-3.19 to -1.51] vs -1.68 [-2.27 to -0.56], p = 0.03), and rhinorrhea (-2.48 [-3.74 to -1.49] vs -1.59 [-2.88 to -0.87], p = 0.04) scores were significantly higher in group 1 compared to group 2. There were significantly higher improvements in ocular symptoms domain score (-1.75 [-3.12 to -1.00] vs -0.50 [-2.31 to -0.31], p = 0.002), nasal symptoms domain score (-2.25 [-4.06 to -1.50] vs -1.25 [-2.37 to -0.68], p = 0.004), and total RQLQ score (-1.98 [-2.67 to -0.88] vs -1.10 [-2.06 to -0.25], p = 0.02) and reduced need for rescue medication use in group 1 compared to group 2 at the end of 4 weeks. CONCLUSION: Standard wraparound eyeglasses can provide a safe, convenient, and effective measure for protection from pollens in patients with SAR.
Authors: Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek Journal: Int Forum Allergy Rhinol Date: 2018-02 Impact factor: 3.858
Authors: Zeynep Çelebi Sözener; Betül Özdel Öztürk; Ömür Aydın; Yavuz Selim Demirel; Nur Münevver Pınar; Sevim Bavbek; Betül Ayse Sin; Dilşad Mungan Journal: Asia Pac Allergy Date: 2021-04-21